Horizon Therapeutics (HZNP) jumps after confirming takeover talks with 3 parties
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Jefferies sees up to 90% chance Horizon Therapeutics (HZNP) gets acquired, with $125 base case
December 1, 2022 11:06 AM ESTJefferies analyst Akash Tewari was the latest Wall Street analyst to weigh in on the takeover prospects of Horizon Therapeutics (NASDAQ: HZNP) after the company announced Tuesday that it is in preliminary talks with three large pharmaceutical companies about a potential buyout.
Tewari is positive on the prospects of a deal and sees one happening in the $25-$30 billion range, which he also said does not bake in Tepezza peak sales of $4 billion.
The analyst said the... More
'Compelling value' in Viridian Therapeutics following Horizon Therapeutics acquisition talks
November 30, 2022 10:39 AM ESTShares of Viridian Therapeutics (NASDAQ: VRDN) jumped Wednesday on the back of news on Tuesday evening that Horizon Therapeutics (NASDAQ: HZNP) is in "highly preliminary discussions" with three large pharmaceutical companies.
Horizon Therapeutics shares are up more than 27% during Wednesday's session, while Viridian Therapeutics has also reacted to the news, currently up over 13%.
Within Horizon's portfolio of... More
Horizon Therapeutics seen worth up to $140/share in takeover
November 30, 2022 8:12 AM ESTSeveral Wall Street analysts put pencil to paper after Horizon Therapeutics (NASDAQ: HZNP) said Tuesday evening that it was in "highly preliminary" takeover talks with Amgen Inc. (NYSE: AMGN), Janssen Global Services, LLC (NYSE: JNJ), and Sanofi (NYSE: SNY). A deal price as high as $140 per share was the high watermark discussed by at least two analysts.
Cowen analyst Ken Cacciatore said that given their belief that Tepezza's previous pause was... More
Horizon Therapeutics (HZNP) resumes trading, up 39%
November 29, 2022 4:55 PM ESTHorizon Therapeutics (NASDAQ: HZNP) resumes trading, up 39%
Horizon Therapeutics (HZNP) Confirms Talks on Takeover With Three Large Pharma Cos.
November 29, 2022 4:26 PM ESTThe Board of Horizon Therapeutics plc (Nasdaq: HZNP) confirms that it is engaged in highly preliminary discussions with Amgen Inc. (NYSE: AMGN), Janssen Global Services, LLC (NYSE:... More
Horizon Therapeutics (HZNP) Fields Takeover Interest - WSJ
November 29, 2022 4:22 PM EST(Updated - November 29, 2022 4:25 PM EST)
Horizon Therapeutics (NASDAQ: HZNP) is fielding takeover interest from large pharmaceutical companies, according to a report from the Wall Street Journal, citing people familiar with the the matter.
With a typical takeover premium it could fetch a price well over $20 billion.
... More